Sign In
Buy ADAG
$3.75
+0.0200 (+0.536%)
At Close: Jul 31, 2026
Adagene to Participate in Two Investor Conferences in September
08:05am, Tuesday, 26'th Aug 2025
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
10:40am, Thursday, 21'st Aug 2025
Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
04:05pm, Tuesday, 12'th Aug 2025
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
07:00am, Tuesday, 08'th Jul 2025
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Ada
Adagene announces up to $25 million strategic investment from Sanofi
07:00am, Tuesday, 01'st Jul 2025
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug
Adagene to Present at Jefferies Global Healthcare Conference 2025
07:30am, Tuesday, 27'th May 2025
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
08:00am, Monday, 28'th Apr 2025
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transfor
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, tod
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
08:00am, Monday, 24'th Mar 2025
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
08:00am, Thursday, 13'th Mar 2025
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, tod
Adagene to Present at Leerink's Global Healthcare Conference 2025
08:00am, Thursday, 06'th Mar 2025
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, tod
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
08:00am, Thursday, 27'th Feb 2025
- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSW
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
